Autoimmune hemolytic anemia (AIHA) is a condition in which your immune system mistakenly produces antibodies that attack and destroy your own red blood cells faster than your body can replace them. It is uncommon but far from trivial, and the destruction of red blood cells can range from a slow, barely noticeable process to a life-threatening crisis requiring emergency transfusion. What makes AIHA tricky, both for patients and clinicians, is that it comes in several distinct forms driven by different antibody types, can appear on its own or alongside other diseases, and resists simple one-size-fits-all treatment.
How Red Blood Cells Get Destroyed
The basic problem in AIHA is that antibodies latch onto the surface of your red blood cells, flagging them for destruction. What happens next depends on the type of antibody involved. In the most common form, warm AIHA, IgG antibodies coat the red blood cells at normal body temperature. Immune cells in the spleen and liver recognize the antibody-tagged cells and eat them, a process called extravascular hemolysis because it happens outside the bloodstream, primarily in the spleen.1Blood. How I treat warm autoimmune hemolytic anemia In cold agglutinin disease, IgM antibodies bind to red blood cells at cooler temperatures (typically in the fingers, toes, nose, and ears) and activate the complement system, a chain reaction of proteins that can punch holes directly in red blood cell membranes. This leads to both intravascular hemolysis (destruction within blood vessels) and extravascular hemolysis in the liver.2PubMed Central. Cold Agglutinin Disease
Complement activation is not exclusive to cold-type AIHA. A meaningful fraction of patients with warm antibodies also trigger complement, which can worsen the destruction and occasionally cause intravascular hemolysis even in the warm form.3PubMed Central. Complement inhibitors to treat IgM-mediated autoimmune hemolysis This overlap between antibody types and destruction pathways is one reason AIHA can be harder to classify and treat than it seems at first glance.
Warm, Cold, and the Rarer Subtypes
Warm AIHA accounts for roughly 70 to 80 percent of all cases. It can strike at any age and runs a chronic course with relapses in many patients. Cold agglutinin disease tends to affect older adults and is driven by IgM antibodies that clump red blood cells together in cooler parts of the circulation. Some patients have a mixed type, with both warm and cold antibodies active simultaneously, which tends to be harder to manage.
A less common but clinically distinct subtype is paroxysmal cold hemoglobinuria (PCH), caused by a biphasic IgG antibody known as the Donath-Landsteiner antibody. This antibody binds to red blood cells at cold temperatures and fixes complement to the cell surface, but the actual destruction happens when the blood warms back up to body temperature and the complement cascade runs to completion.4PubMed Central. Applying Donath-Landsteiner test for the diagnosis of paroxysmal cold hemoglobinuria PCH is rare in adults but is actually the most common form of AIHA in young children, often triggered by a viral infection and typically self-limited.5PubMed Central. Recurrent Donath-Landsteiner hemolytic anemia: a pediatric case report
Primary Versus Secondary AIHA
When no underlying disease can be found, AIHA is classified as primary or idiopathic. But in many patients, AIHA shows up alongside or because of another condition, making it secondary. The most common culprits include lymphoproliferative disorders (such as chronic lymphocytic leukemia and lymphomas), other autoimmune diseases like lupus, and certain infections.
The distinction matters for outcomes. In one retrospective analysis, patients with secondary AIHA linked to lymphoproliferative disease were older on average, had a higher recurrence rate (about a third relapsed compared to roughly 8 percent in primary AIHA), and had significantly shorter progression-free survival.6Scientific Reports. Characteristics of patients with autoimmune haemolytic anaemia secondary to lymphoproliferative disorder: A single-centre retrospective analysis These patients also had a mortality rate about four times higher than those with primary disease. When AIHA is secondary, treating the underlying condition is essential, not just managing the hemolysis itself.
Infections can trigger AIHA as well, sometimes dramatically. Epstein-Barr virus, Mycoplasma pneumoniae, and various other pathogens have all been linked to acute hemolytic episodes. In one reported case, EBV-related cold agglutinin disease led to peripheral gangrene, a rare but serious complication of the clumping of red blood cells in small vessels.7PubMed Central. Cold autoimmune haemolytic anaemia secondary to Epstein Barr virus infection presenting with peripheral gangrene; case report In most infection-triggered cases, the hemolysis resolves once the infection clears, and treatment is supportive.
When Medications Are the Cause
Certain drugs can cause an immune hemolytic anemia that looks virtually identical to AIHA. Drug-induced immune hemolytic anemia (DIIHA) can occur through two main mechanisms. In one, the drug prompts the body to make antibodies that only react in the presence of the drug itself. Cephalosporin antibiotics are a classic example. In the other, the drug triggers the production of true autoantibodies that attack red blood cells even without the drug present, making the picture indistinguishable from warm AIHA in the lab.8PubMed. Drug-induced immune hemolytic anemia The key difference is that DIIHA resolves when the offending drug is stopped.9Immunohematology. Drug-induced immune hemolytic anemia: the last 30 years of changes This is an important consideration because misidentifying DIIHA as primary AIHA can lead to unnecessary immunosuppressive treatment when simply discontinuing the drug would solve the problem.
How AIHA Is Diagnosed
The direct antiglobulin test, commonly known as the Coombs test, is the cornerstone of diagnosis. It detects antibodies or complement proteins stuck to the surface of red blood cells, and can distinguish between warm IgG-coated cells, complement-coated cells (common in cold types), and mixed patterns. This classification guides treatment, since warm and cold forms require different approaches.10PubMed. Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias
The challenge is that the Coombs test is not always positive. A subset of patients with convincing clinical and laboratory signs of AIHA have a negative result, so-called DAT-negative AIHA. This can happen when the amount of antibody on each red blood cell is too low for the standard test to detect, when the antibodies are IgA or IgM types the standard reagent does not pick up, or when the antibodies have low binding affinity.11PubMed. DAT-Negative Autoimmune Hemolytic Anemia DAT-negative AIHA can lead to delayed diagnosis and inappropriate therapy, because clinicians may not consider an immune cause for the hemolysis if the standard screening test is negative. Specialized techniques such as flow cytometry and more sensitive immunoassays exist but are available only in a handful of reference laboratories.
First-Line Treatment and the Steroid Problem
For warm AIHA, corticosteroids remain the standard first-line treatment and produce an initial response in roughly 70 to 85 percent of patients.12PubMed Central. Treatment of autoimmune hemolytic anemias The response can be rapid, sometimes visible within days. One real-world study found that starting steroids intravenously rather than orally led to significantly higher initial response rates.13PubMed. Systemic corticosteroids in the treatment of warm autoimmune hemolytic anemia: A clinical setting perspective However, the catch is that steroids need to be tapered slowly over many months, and a substantial number of patients relapse during or after tapering.
Patient experience data paints a more complicated picture than response rates alone suggest. In qualitative research, every patient interviewed reported side effects from oral corticosteroids, including mood swings, sweating, nausea, and swollen limbs. Several described how quickly severe side effects returned if they missed a dose of high-dose prednisone. Some patients expressed a strong desire to avoid future steroid use despite its effectiveness, reflecting the tension between a drug that controls hemolysis and one that significantly impairs quality of life.14Blood. Qualitative Examination of Treatment Experiences Among Individuals Living with Warm Autoimmune Hemolytic Anemia (wAIHA) All participants in that study had to modify their work arrangements because of AIHA symptoms or treatment side effects, and fatigue, in particular, was described as a large burden that was difficult to convey to family and health care providers.
When Steroids Are Not Enough
For patients who do not respond to steroids or who relapse when steroids are tapered, rituximab has become the preferred next step for warm AIHA and is also part of the front-line approach for cold agglutinin disease, where steroids alone are generally ineffective.15PubMed Central. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia Rituximab works by depleting B cells, the immune cells responsible for making the harmful antibodies. In one center’s experience, combining low-dose rituximab with high-dose dexamethasone as first-line therapy achieved an initial response in all patients treated, though the durability of responses varied.16Blood Research. Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico
Splenectomy, once a second-line mainstay, is used less frequently now but remains an option for refractory warm AIHA. The spleen is the primary site where antibody-coated red blood cells are destroyed, so removing it can reduce hemolysis. In a surgical outcomes study, short-term complete response was achieved in about 61 percent of patients, but by the last follow-up (median of about 33 months), the complete response rate had settled to around 43 percent, with nearly 40 percent maintaining a partial response. Most patients with secondary AIHA still required ongoing medication even after spleen removal.17PubMed. Clinical and surgical outcomes of splenectomy for autoimmune hemolytic anemia
Newer and Emerging Therapies
Cold agglutinin disease, which does not respond well to standard immunosuppression, has seen a significant advance with sutimlimab, a monoclonal antibody that blocks a key component of the classical complement pathway. In a clinical trial, over half the patients met the composite primary endpoint, hemoglobin levels rose by an average of 2.6 grams per deciliter, and most patients were able to avoid transfusions from week five through the end of the 26-week study period. Fatigue improved as early as the first week.18PubMed. Sutimlimab in Cold Agglutinin Disease Sutimlimab selectively blocks the classical activation pathway while leaving other complement pathways intact, and has been approved in the United States.19PubMed. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?
For warm AIHA, a different class of therapies is in development: drugs that block the neonatal Fc receptor (FcRn). This receptor normally recycles IgG antibodies and extends their lifespan in the body. By blocking it, FcRn inhibitors accelerate the clearance of all IgG, including the autoantibodies driving the hemolysis, potentially producing a rapid reduction in disease activity.20PubMed Central. FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia FcRn blockers have already been approved for other antibody-driven autoimmune conditions and are currently being evaluated in warm AIHA clinical trials.21PubMed. Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia
The Blood Transfusion Dilemma
Transfusing someone with AIHA is one of the most anxiety-producing tasks in transfusion medicine. The autoantibodies circulating in the patient’s blood react with virtually all donor red blood cells, making crossmatch testing come back incompatible. This creates a real and sometimes dangerous hesitation. In one study, the time to issue “best match” blood averaged nearly four hours, and the pre-transfusion hemoglobin in those severely hemolytic patients had dropped to a median of about 5.4 grams per deciliter, which is dangerously low.22PubMed Central. Incompatible blood transfusion: Challenging yet lifesaving in the management of acute severe autoimmune hemolytic anemia
The fear of transfusion reactions in AIHA has historically been overstated. One analysis found that overestimation of the risk associated with positive crossmatches led to three patients receiving no transfusion or delayed transfusion, and those patients died. By contrast, the 32 patients who were transfused had no significant hemolytic reactions from auto- or alloantibodies.23PubMed Central. Precautions surrounding blood transfusion in autoimmune haemolytic anaemias are overestimated Over the decades, transfusion practices in AIHA have improved considerably. The rate of red cell transfusions in AIHA patients dropped from over half to about 20 percent, and the rate of alloimmunization (developing antibodies against donor blood) fell from 30 percent to 6 percent, likely due to better donor-recipient matching and modern blood processing techniques.24PubMed. Transfusions in autoimmune hemolytic anemias: Frequency and clinical significance of alloimmunization The take-home message is that withholding transfusion from a severely anemic AIHA patient out of crossmatch anxiety can be more dangerous than giving the blood.
Blood Clots as an Underappreciated Risk
One of the less-discussed dangers of AIHA is an elevated risk of venous thromboembolism, particularly pulmonary embolism. In one cohort, roughly 11 percent of AIHA patients experienced a blood clot. Markers of more intense hemolysis, especially elevated LDH levels, were independently associated with thrombosis risk.25Journal of Thrombosis and Haemostasis. Intravascular hemolysis and multitreatment predict thrombosis in patients with autoimmune hemolytic anemia A case-control study of warm AIHA found that 20 percent of patients developed venous thromboembolism, all involving pulmonary embolism, and that lower hemoglobin levels at the time of the event were a strong predictor. Many of these patients would not have been flagged as high-risk by standard clinical scoring systems for blood clots.26PubMed. Venous thromboembolism related to warm autoimmune hemolytic anemia: a case-control study
The mechanisms linking hemolysis to clotting are complex but increasingly understood. When red blood cells are destroyed, their membranes release fragments and substances that activate the clotting system, promote platelet aggregation, and impair the normal blood vessel relaxation that prevents clot formation.27PubMed Central. Autoimmune Hemolytic Anemia and Pulmonary Embolism: An Association to Consider This means that the sicker you are from hemolysis, the higher your clotting risk becomes, a vicious combination that argues for aggressive treatment of active flares.
Evans Syndrome and Overlapping Autoimmunity
Some patients with AIHA also develop immune-mediated destruction of platelets, a combination known as Evans syndrome. This dual attack on both red blood cells and platelets makes management harder, because bleeding risk from low platelets compounds the anemia from red cell destruction.28PubMed Central. Evans syndrome: clinical perspectives, biological insights and treatment modalities Evans syndrome is rare and runs a chronic relapsing course. It often prompts a search for an underlying immunodeficiency or systemic autoimmune disease, because its presence can signal broader immune dysregulation.
AIHA in Pregnancy
AIHA during pregnancy, whether pre-existing or newly triggered by pregnancy itself, poses risks to both mother and baby. In one tertiary-care series, all pregnant women with AIHA experienced antepartum complications, and about 44 percent developed preeclampsia. Half the babies were born preterm, and two-thirds had low birth weight.29PubMed Central. Autoimmune Hemolytic Anaemias in Pregnancy: Experience in a Tertiary Care Hospital in South India Identifying the type of antibody involved is particularly important during pregnancy, because IgG antibodies can cross the placenta and potentially affect the fetus, while IgM cannot cross directly but may still contribute to complications through complement-mediated effects on the placenta.30PubMed. Autoimmune hemolytic anemia in pregnancy: a challenge for maternal and fetal follow-up Treatment options are also more limited, since many immunosuppressive drugs carry fetal risks. The condition remains poorly described in the literature, and managing cases that do not respond to steroids requires careful balancing of maternal and fetal safety.31PubMed Central. Pregnancy Induced Autoimmune Warm Antibodies Hemolytic Anemia: A Case Report
AIHA in Children with Lupus
Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases associated with secondary AIHA, and the presentation can differ substantially between children and adults. In a large comparison, about 14 percent of children with lupus had AIHA at diagnosis, compared to only 3 percent of adults. Children also had more severe anemia, more hemorrhagic complications, and were more likely to need red cell transfusions due to bleeding. Constitutional symptoms like fever, weight loss, and organ enlargement were far more common in the pediatric group.32PubMed. Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients For clinicians seeing a child with unexplained hemolytic anemia, lupus is an important diagnosis to consider, especially when other systemic symptoms are present.
Long-Term Outlook and Relapse
AIHA is often chronic and relapsing. In a multicenter cohort of hospitalized adults with primary warm AIHA, about half of those who initially responded to treatment relapsed, with a median time to relapse of roughly four months. Having a very high reticulocyte count at admission was an independent predictor of relapse, reflecting the bone marrow’s attempt to compensate for severe ongoing destruction.33Blood. Treatment response, relapse and survival of hospitalized adult primary warm autoimmune hemolytic anemia: A multicenter retrospective cohort study The mortality in that cohort was substantial: about 32 percent of patients died during follow-up, most commonly from infection rather than the hemolysis itself. The age-standardized death rate was far higher than in the general population.
The severity of anemia at the first episode matters for the long term. More profound anemia at onset correlates with more frequent relapses, greater refractoriness to treatment, and a higher chance of a fatal outcome, likely because severe disease reflects the convergence of highly destructive antibodies, active complement involvement, and inadequate bone marrow compensation.34PubMed. Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures This underscores why early, aggressive treatment of severe presentations is so important, and why relapse prevention is an active area of research as newer agents reach the clinic.